Los Angeles Biotechnology Network
  • Home
  • About
  • Contact
News Ticker
  • [ July 27, 2021 ] Southern California StemCyte Inc. Receives AABB Reaccreditation News
  • [ July 27, 2021 ] Supervisor of Microbiology – Los Robles Hospital and Medical Center – Thousand Oaks, CA Los Angeles Biotech Jobs
  • [ July 27, 2021 ] Candel gets busy IPO week moving with downsized raise as Rajiv Shukla’s third SPAC goes public News
  • [ July 27, 2021 ] RARE-X Appoints Charlene Son Rigby as Chief Executive Officer News
  • [ July 27, 2021 ] Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio News
HomeFeatured NewsUncategorizedFor UCLA-based startup, new muscular dystrophy treatment is a personal mission

For UCLA-based startup, new muscular dystrophy treatment is a personal mission

February 24, 2021 Los Angeles Biotechnology Network News Featured NewsUncategorized, News Comments Off on For UCLA-based startup, new muscular dystrophy treatment is a personal mission

The post For UCLA-based startup, new muscular dystrophy treatment is a personal mission appeared first on Life Sciences.

Click to view original post

Previous

Research Associate – SigmaGraft Biomaterials Inc. – Fullerton, CA

Next

Molecular Biologist III – Thermo Fisher Scientific – Carlsbad, CA

Recent Posts

  • Southern California StemCyte Inc. Receives AABB Reaccreditation
  • Supervisor of Microbiology – Los Robles Hospital and Medical Center – Thousand Oaks, CA
  • Candel gets busy IPO week moving with downsized raise as Rajiv Shukla’s third SPAC goes public
  • RARE-X Appoints Charlene Son Rigby as Chief Executive Officer
  • Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio

Copyright © 2021 | MH Magazine WordPress Theme by MH Themes